Moderna and Merck disclosed five-year results from their Phase IIb trial of intismeran autogene in combination with Keytruda in high-risk melanoma patients. The data showed a 49% reduction in the risk of recurrence or death compared with Keytruda alone. Of the 312 participants enrolled, 76% remained recurrence-free at five years versus 52% in the control arm. The safety profile was consistent with prior reports, with Grade 3 or higher adverse events observed in 14% of patients, aligning with expectations for checkpoint inhibitor–based regimens. These robust long-term outcomes bolster Moderna’s oncology pipeline and may accelerate discussions with regulatory authorities about a potential registrational trial, positioning the personalized mRNA therapy as a key growth driver beyond its vaccine business.

In a January interview at the World Economic Forum, Moderna CEO Stéphane Bancel stated that the company will not initiate new late-stage vaccine trials in light of growing skepticism toward immunizations among U.S. policymakers. He cited an increasingly challenging environment for obtaining trial approval and public funding, noting that Moderna plans to reallocate resources toward oncology and rare disease programs. This strategic pivot follows a period in which the respiratory vaccine portfolio underperformed expectations, and underscores management’s intent to focus R&D spending on segments with clearer regulatory pathways and higher margin potential. Investors should monitor the impact on Moderna’s vaccine pipeline timelines and the company’s overall R&D expenditure allocation for 2026 and beyond.